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Sexual Dysfunction
Changes in Sexual Function in Benign Prostatic Hyperplasia 
Patients Taking Dutasteride: 1-Year Follow-Up Results
Byung Hoon Chi, Sae Chul Kim
Department of Urology, Chung-Ang University College of Medicine, Seoul, Korea
Purpose: Sexual adverse events (AEs), a major cause for discontinuing 5α-reductase 
inhibitor (5ARI) therapy for benign prostatic hyperplasia (BPH), are known to occur 
most frequently early in therapy and appear to decline over time. The aim of this study 
was to investigate the changes in sexual function occurring with dutasteride treatment 
during a 1-year follow-up period in Korean men. 
Materials and Methods: Using the International Index of Erectile Function, we pro-
spectively evaluated, after 1, 3, 6, 9, and 12 months of treatment, the changes in sexual 
function of 55 outpatients (mean age 62.3±7.2 years) with BPH (mean volume 48.9±16.0
g) who had relatively good erectile function (EF) and were treated with dutasteride for 
at least 1 year. 
Results: EF scores showed the most significant decrease at 1 month (p＜0.01). Function 
gradually recovered thereafter but was still significantly decreased after 12 months 
of treatment (p＜0.05). The scores for orgasmic function and sexual desire also showed 
the most significant reduction at 1 month  but were restored to the baseline level at 
6 months. No significant correlation was observed between changes in sexual function 
and prostate-specific antigen level, prostate volume, or International Prostate 
Symptom Scores.
Conclusions: After 1 month of treatment, dutasteride therapy resulted in a significant 
reduction in all investigated sexual functions. Overall, recovery in sexual function was 
noted at 3 months, and orgasmic function and sexual desire were restored to baseline 
levels at 6 months. However, EF was still significantly reduced at 12 months. 
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INTRODUCTION
The modern lifestyle and continuously growing aging pop-
ulation in Korea have driven an increase in the prevalence 
of benign prostatic hyperplasia (BPH) [1], which impairs 
men’s quality of life with lower urinary tract symptoms 
(LUTS). For symptomatic BPH, medical therapy can be 
largely categorized into α-blockers and 5α-reductase in-
hibitors (5ARIs). The α1 type of receptor is predominant in 
the prostate. Therefore, α1 receptor blockers reduce the 
functional obstruction of the prostate gland [2,3]. 5ARI in-
hibits the conversion of testosterone to 5α-dihydrotestoste-
rone (DHT), which is primarily responsible for the initial 
development and subsequent enlargement of the prostate 
gland [4]. Thus, 5ARIs reduce LUTS scores by reducing 
prostate volume by 20% to 30% [5]. The major adverse 
events (AEs) of 5ARIs include sexual dysfunction, such as 
erectile dysfunction (ED), decreased libido, and ejacu-
latory dysfunction (EjD). A large-scale literature review 
showed that, after 2 years of finasteride therapy, about 12% 
of patients had to discontinue treatment owing to sexual 
AEs, thereby confirming the significance of sexual AEs as 
a major cause of treatment discontinuation [6]. According 
to existing evidence, sexual AEs occur at similar rates re-
gardless of which 5α-reductase isoform is inhibited [7]. 
Sexual AEs occur most frequently early in therapy, and Korean J Urol 2011;52:632-636
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TABLE 1. Characteristics of the 55 patients who completed the 
study
Characteristics Mean±SD
Age (yr)
Baseline IIEF scores
    Total 
    Erectile function 
    Intercourse satisfaction 
    Orgasm function 
    Sexual desire 
    Overall satisfaction 
PSA (ng/ml)
IPSS, total
Prostate volume, total (g) 
adenoma (g)
62.3±7.2
  50.4±11.5
22.0±5.0
  8.1±2.1
  7.5±2.1
  6.1±1.4
  6.7±1.6
  2.2±1.5
17.9±6.6 
  48.9±16.0 
  22.7±15.1 
SD: standard deviation, IIEF: International Index of Erectile 
Function, PSA: prostate-specific antigen, IPSS: International
Prostate Symptom Score
TABLE 2. International Prostate Symptom Score (IPSS), uroflow
rate, and prostate volume at baseline and after 12 months of 
treatment with dutasteride
Baseline 12 months  p-value
IPSS
    Total
    Obstructive
       symptoms
    Irritative symptoms
Quality of life
Uroflow rate
    Qmax (ml/s)
    Average flow rate 
      (ml/s)
    Residual urine (ml)
Prostate volume (g)
17.9±6.6
  9.9±5.4
  8.0±4.0
  3.8±1.3
13.5±6.7
  7.3±3.8
  25.8±51.3
  48.9±16.0
12.4±6.3
  6.8±3.9
  5.6±2.9
  2.9±1.0
14.0±5.5
  12.6±37.6
     18±32.1
  33.7±18.3
＜0.001
＜0.001
＜0.001
0.019
0.031
0.70
0.026
0.038
seem to decline over time, in patients using either dutas-
teride or finasteride [8-10]. 
The aim of this study was to investigate the changes in 
sexual function during a 1-year follow-up period of dutas-
teride therapy in Korean patients with BPH. 
MATERIALS AND METHODS
To prospectively evaluate changes in sexual function dur-
ing 1 year of treatment with dutasteride, we recruited 73 
patients with BPH who had an enlarged prostate (total vol-
ume ≥30 g), had LUTS (International Prostate Symptom 
Score [IPSS] ＞10), and were undergoing combined treat-
ment with α-blockers (tamsulosin or doxazosin) and dutas-
teride from January 2007 to July 2009. The patients had 
relatively good erectile function (EF), defined as an 
International Index of Erectile Function (IIEF) EF domain 
score ≥17, and had sexual intercourse at least once per 
month. To rule out the independent effect of α-blockers on 
sexual function, all patients were treated with an α-blocker 
alone for 1 month before the combined treatment with an 
α-blocker and dutasteride. During the study period, 55 pa-
tients completed the treatment; however, 18 patients drop-
ped out in violation of the study (violation of visit day in 3, 
no sexual intercourse owing to patient’s operation or sick-
ness or partner’s illness in 3, sexual dysfunction in 2, and 
failure to follow-up in 10).
IPSS, peak flow rate, post-void residual urine, IIEF 
scores, prostate volume by transrectal ultrasonography, 
and serum prostate-specific antigen (PSA) levels were 
measured before and periodically during treatment. 
Sexual function during dutasteride therapy was analyzed 
by total IIEF scores, EF domain scores (Q1, 2, 3, 4, 5, and 
15), sexual intercourse satisfaction scores (Q6, 7, and 8), 
orgasmic function scores (Q9 and 10), sexual desire scores 
(Q11 and 12), and overall satisfaction scores (Q13 and 14). 
Patients with post-void residual urine volume ≥100 ml, 
PSA levels ≥4 ng/ml, or contraindications for α-blockers 
and dutasteride were excluded from the study. 
Changes in sexual functions were prospectively eval-
uated at 1 month after treatment with α-blocker and at 1, 
3, 6, 9, and 12 months after combined treatment with dutas-
teride and α-blocker. The possibilities of sexual AEs with 
both α-blockers and dutasteride were explained before the 
initiation of medication. SPSS ver. 14.0 (SPSS Inc., 
Chicago, IL, USA) was used for statistical analysis. The 
IIEF scores between baseline and 1 month after treatment 
with α-blocker, between baseline and throughout com-
bined treatment with dutasteride and α-blocker, and be-
tween 1 month after treatment with α-blocker and 
throughout combined treatment with dutasteride and 
α-blocker were compared by using the paired t-test. 
Correlations between changes in IIEF scores and changes 
in IPSS scores, prostate volume, and PSA levels were ana-
lyzed by using the Pearson’s correlation test. A p-value less 
than 0.05 was set as statistically significant.
RESULTS
The average age of the patients was 62.3±7.2 years. The 
mean pretreatment PSA level and prostate volume were 
2.2±1.5 ng/ml and 48.9±16.0 g, respectively (Table 1). IPSS 
and quality of life were significantly improved and prostate 
volume was significantly reduced at 12 months after treat-
ment with dutasteride (Table 2).
After 1 month of treatment with alpha-blockers alone, 
for both tamsulosin and doxazosin, no significant changes 
in IIEF scores from the pretreatment level were shown. 
However, the IIEF scores showed the most significant re-
duction at 1 month after combined treatment with an 
α-blocker and dutasteride (p＜0.01) and then gradually re-
covered, although EF was still significantly decreased at 
12 months (p＜0.05) (Table 3). 
We studied the changes in each domain score of the IIEF 
after adding dutasteride to the α-blocker treatment. The 
EF and overall satisfaction domain scores showed the most Korean J Urol 2011;52:632-636
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TABLE 3. Changes in IIEF scores after 1 month of treatment with an alpha-blocker and during dutasteride treatment in addition to
the alpha-blocker for 12 months
IIEF
domains
IIEF scores (Mean±SD)  
α-blocker Dutasteride
Before  1 month 1 month 3 months 6 months 9 months 12 months
Total  
EF
IS
OF
SD
OS
50.7±11.5
22.0±5.0
8.4±1.5
7.5±2.1
6.1±1.4
6.7±1.6
50.6±10.6
22.2±4.6
8.1±1.5
7.6±2.0
6.4±1.5
6.3±1.3
38.4±15.1
a
15.7±7.4
a
6.8±2.0
a
5.8±1.9
a
4.7±1.7
a
5.4±1.8
a
41.7±15.8
a
17.4±8.1
a
7.1±2.1
b
6.3±2.2
a
5.2±1.8
a
5.7±1.8
a
  45.5±16.3
a
19.0±7.5
a
7.8±2.3
6.9±2.3
5.8±1.8
  6.0±1.9
b
44.9±17.3
a
18.7±8.2
a
7.8±2.1
6.9±2.2
5.7±1.9
5.8±2.2
b
  47.2±14.4
b
20.3±6.7
b
8.0±2.2
7.0±2.0
5.8±1.5
  6.1±1.8
b
EF: erectile function, IS: intercourse satisfaction, OF: orgasmic function, SXD: sexual desire, OS: overall satisfaction, 
a: p＜0.01, 
b: p＜0.05
FIG. 2. Percentile of patients with moderate to severe erectile 
dysfunction (ED) during 12 months of treatment according to 
International Index of Erectile Function-erectile function score.
FIG. 1. Changes in International Index of Erectile Function- 
erectile function score during 12 months of treatment.
significant decrease at 1 month after treatment (p＜0.01) 
and gradually recovered thereafter, but were still sig-
nificantly decreased at 12 months (p＜0.05). Moderate to 
severe ED (EF score ＜17) was seen in 38% of patients at 
1 month after treatment and in 22% of patients at 12 
months after treatment (Fig. 1, 2). The scores for inter-
course satisfaction, orgasmic function, and sexual desire 
also showed the most significant reduction at 1 month after 
treatment, but they were restored to baseline levels at 6 
months after treatment.
No significant correlation was observed between the 
change in each sexual function and those in PSA level, pros-
tate volume, or IPSS scores.
DISCUSSION 
To enable BPH development, testosterone must be con-
verted to its active form, DHT, by the enzyme 5-al-
pha-reductase. DHT levels in the prostate remain normal 
despite the reduction in testosterone that occurs with aging 
[11]. Two genes have been identified that encode for the iso-
enzymes 5-alpha-reductase types 1 and 2. The type 1 iso-
enzyme is found in the liver at birth and in two waves in 
the skin: from just before birth until 2 or 3 years of age and 
then again from puberty through adulthood. More re-
cently, type 1 mRNA has also been found in prostate tissue. 
The type 2 isoenzyme is found in all prostate tissue, seminal 
vesicles, epididymis, fetal genital skin, and in the skin and 
scalp from just before birth until 2 or 3 years of age as well 
as in the adult liver [12]. 
Inhibiting the conversion of testosterone to DHT in pe-
ripheral tissues may have implications for the treatment 
of BPH. Finasteride inhibits 5-alpha-reductase type 2, 
with little affinity for type 1. It has been shown to be effec-
tive in lowering plasma DHT levels by approximately 75% 
to 80%, leading to a reduction in prostate volume and im-
proved symptoms in men with BPH [11]. Dutasteride in-
hibits both type 1 and type 2 5-alpha-reductase iso-
enzymes, reducing circulating DHT by more than 90% [13].
Although the efficacy and safety of 5ARIs for the treat-
ment of enlarged prostates have been well documented, 
sexual AEs have been reported. ED was the most common 
sexual AE of finasteride. In a meta-analysis conducted by 
the American Urological Association (AUA) BPH guide-
lines committee, the rate of ED in finasteride-treated 
groups was 8%, compared with 4% in patients treated with Korean J Urol 2011;52:632-636
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placebo [14]. One study reported that 6 months of finas-
teride therapy caused ED in 22% of patients at 3 months 
and 33% at 6 months [15]. 
EjD and decreased libido are the most common sexual 
AEs after ED. According to the same meta-analysis by the 
AUA guideline committee, the rate of decreased libido and 
EjD were 5% vs. placebo 3% and 4% vs. placebo 1%, re-
spectively [14].
The sexual AE profile of dutasteride appears to be sim-
ilar to that of finasteride with regards to ED, EjD, and de-
creased libido [7]. In a direct comparative study of 1 year 
duration, 1630 patients with LUTS taking dutasteride and 
finasteride experienced comparable incidences of ED (7% 
vs. 8%, respectively), decreased libido (5% vs. 6%), and EjD 
(1% vs. 1%) [16]. In this study, moderate to severe ED was 
experienced in 38% of patients at 1 month and in 22% of 
patients at 12 months after treatment initiation. 
The pathophysiology of sexual function produced by 
5ARIs may be related to reduction of DHT levels. In an ani-
mal study, Park et al reported that DHT improved gene ex-
pression of nitric oxide synthase (NOS) in the corpus cav-
ernosum and played an important role in maintaining NOS 
activity [17]. DHT is more potent than testosterone in in-
creasing NOS activity in rats [17]. A report demonstrated 
that 5ARIs caused reduction in NOS activity in the corpus 
cavernosum and reduction of the erectile response to elec-
trical stimulation [18]. However, Mondaini et al suggested 
a noxious effect on the basis of the observation that blind 
administration of finasteride was associated with a sig-
nificantly higher proportion of sexual dysfunction in pa-
tients counseled about potential sexual AEs than in those 
from whom the same information was withheld [19].
One might assume that a positive correlation would exist 
between length of therapy and degree of sexual dysfunc-
tion. However, in patients using either dutasteride or fi-
nasteride, sexual AEs occur most frequently early in ther-
apy and appear to decline over time. The Proscar Long 
Term Efficacy and Safety Study (PLESS) reported a preva-
lence of 22% of one or more sexual AEs during the first year 
of treatment [8]. The difference between the finasteride 
group and placebo disappeared, with the exception of de-
creased ejaculatory volume [9]. In one study, patients who 
received dutasteride for 48 months reported reduction in 
the incidence of drug-related sexual dysfunctions to less 
than 0.5% by the end of the fourth year [8]. In this study, 
dutasteride therapy resulted in the most significant reduc-
tion of every sexual function domain score at 1 month after 
treatment. Overall sexual function recovery was observed 
at 3 months after treatment, and orgasmic function and 
sexual desire were restored to the baseline level at 6 
months after treatment. However, EF was still sig-
nificantly reduced at 12 months after treatment.
Testosterone is associated not only with EF, but also with 
libido and semen production. Likewise, DHT may be re-
lated to libido and appears to regulate both semen volume 
and viscosity through its action on the development and 
function of the prostate and seminal vesicles [20,21]. 5ARIs 
reduce blood DHT levels by over 70% but induce a compen-
satory rise in testosterone level by 20% [22]. Future re-
search is needed to either confirm or refute the hypothesis 
that a reduction in the DHT level has a greater impact on 
sexual function than the compensatory increase in testos-
terone level and to explain why sexual AEs occur early in 
5ARI therapy and decline over the duration of treatment. 
CONCLUSIONS
Dutasteride therapy resulted in the most significant reduc-
tion in all IIEF sexual function domain scores at 1 month 
after treatment. Overall recovery in sexual function was 
noted after 3 months of treatment, and orgasmic function 
and sexual desire were restored to baseline levels after 6 
months of treatment. However, the EF score was still sig-
nificantly reduced at 12 months. No significant correlation 
was observed between changes in sexual function and 
IPSS, serum PSA level, or prostate volume. 
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